Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-b4m5d Total loading time: 0 Render date: 2025-02-23T12:50:11.198Z Has data issue: false hasContentIssue false

Solifenacin

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Solifenacin succinate ((3R)-1-azabicyclo[2.2.2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate compound with butaneodioic acid (1:1)) has a molecular weight of 480.6 and a molecular formula of C23H26N2O2,C4H6O4. Solifenacin succinate 5 mg is equivalent to solifenacin 3.8 mg. Dosage of solifenacin succinate is expressed in terms of the salt.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 473 - 484
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Wagg, A, Wyndaele, JJ, Sieber, P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4(1): 14–24.CrossRefGoogle ScholarPubMed
Zesiewicz, TA, Evatt, M, Vaughan, CP, Jahan, I, Singer, C, Ordorica, R, Salemi, JL, Shaw, JD, Sullivan, KL. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(5): 514–520.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Chancellor, MB, Zinner, N, Whitmore, K, Kobashi, K, Snyder, JA, Siami, P, Karram, M, Laramée, C, Capo, JP, Jr, Seifeldin, R, Forero-Schwanhaeuser, S, Nandy, I. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008; 30(10): 1766–1781.CrossRefGoogle ScholarPubMed
Haab, F, Cardozo, L, Chapple, C, Ridder, AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47(3): 376–384.CrossRefGoogle ScholarPubMed
Herschorn, S, Pommerville, P, Stothers, L, Egerdie, B, Gajewski, J, Carlson, K, Radomski, S, Drutz, H, Schulz, J, Barkin, J, Hirshberg, E, Corcos, J. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin 2011; 27(2): 375–382.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Lua, LL, Pathak, P, Dandolu, V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn 2017; 36(8): 2123–2131.CrossRefGoogle ScholarPubMed
Malcher, MF, Droupy, S, Berr, C, Ziad, A, Huguet, H, Faillie, JL, Serrand, C, Mura, T. Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French national medical-administrative database. J Urol 2022; 208(4): 863–871.CrossRefGoogle ScholarPubMed
Solifenacin. Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 31 December 2022 via www.medicinescomplete.com.Google Scholar
Solifenacin. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 31 December 2022 via www.micromedexsolutions.com.Google Scholar
Summary of Product Characteristics – Vesicare 10 m film-coated tablets. Astellas Pharma Ltd. Electronic Medicines Compendium: Vesicare 10 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 31 December 2022 via www.medicines.org.uk.Google Scholar
Vouri, SM, Kebodeaux, CD, Stranges, PM, Teshome, BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2017; 69: 77–96.CrossRefGoogle ScholarPubMed
Wagg, A, Gibson, W, Ostaszkiewicz, J, Johnson, T, 3rd, Markland, A, Palmer, MH, Kuchel, G, Szonyi, G, Kirschner-Hermanns, R. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. Neurourol Urodyn 2015; 34(5): 398–406.CrossRefGoogle ScholarPubMed
Yang, N, Wu, Q, Xu, F, Zhang, X. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis. J Int Med Res 2021; 49(9): 3000605211042994.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Solifenacin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.048
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Solifenacin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.048
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Solifenacin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.048
Available formats
×